The information in the press release is intended for investors.
Isofol has received further results from the laboratory tests carried out as part of the company's stepwise process to enable a cost-effective evaluation of the drug candidate arfolitixorin. The results originate from tests on organoids from tumors in the colon and rectum and show additional effects of arfolitixorin in two of a total of five organoids studied, an effect that was not seen with leucovorin. The additional effect was shown as an enhancement of the response to the chemotherapy drug 5-FU, both in terms of reducing tumor size and the ability to induce cell death. In three out of five organoid tests, however, no additional effect of any of the folates in combination with 5-FU was seen.
Data from the laboratory tests will undergo bioinformatics analyses to identify molecular patterns associated with folate sensitivity. These analyses may provide further support in the construction of a hypothesis for the continued development of arfolitixorin.
"These results show positive signals that we did not see in organoids from pancreatic tumors and give us further guidance in the choice of indication for a potential clinical trial. We will therefore look further into this and the upcoming tests will become even more important," says Isofol's acting CEO,
As part of the company's stepwise process, several laboratory tests are carried out to evaluate the effect of arfolitixorin in different doses together with the chemotherapy drug 5-FU and in other possible combination treatments. The tests are carried out in collaboration with external research laboratories in
For more information, please contact
E-mail: roger.tell@isofolmedical.com
Phone: +46 (0) 760 29 39 11
This information is information that
About Isofol Medical AB (publ)
www.isofolmedical.com
https://news.cision.com/isofol-medical-ab--publ-/r/isofol-presents-additional-results-from-laboratory-tests-with-arfolitixorin-showing-supplementary-ef,c3900656
https://mb.cision.com/Main/15598/3900656/2516324.pdf
(c) 2023 Cision. All rights reserved., source